3-chloro-4-methylpenta-1,3-diene | 63755-60-2

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 乙烯基卤化物
• 英文名称: 3-chloro-4-methylpenta-1,3-diene
• 英文别名: 3-Chlor-4-methyl-penta-1,3-dien
• CAS: 63755-60-2
• 化学式: C₆H₉Cl
• 分子量: 116.59
• InChiKey: MIKFDMAYKHGNAG-UHFFFAOYSA-N

物化性质

• 沸点：
  129.1±9.0 °C(Predicted)
• 密度：
  0.916±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  6,6-dichloro-1-methyl-3-thiabicyclo<3.1.0>hexane 3,3-dioxide 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 3-chloro-4-methylpenta-1,3-diene
  参考文献：
  名称：

  Lithium aluminium hydride promoted extrusion of SO2 from sulfolenes and sulfolene-adducts. 1,3-dienes, 3-chloro- and 3,3-dichloro-1,4-dienes and skipped polyenes

  摘要：

  DOI：

  10.1016/s0040-4039(01)92799-6

文献信息

• Addition of Chloroprene Grignards to Aromatic Aldehydes: Synthesis of Homoallenyl Alcohols
  作者：Arne G. A. Geissler、Bernhard Breit

  DOI：10.1021/acs.orglett.1c00527

  日期：2021.4.2

  A general procedure for the one-pot synthesis of racemic homoallenyl alcohols from the corresponding aldehyde and chloroprene-derived Grignards is described. Employing bis[2-dimethylaminoethyl]ether (BDMAEE) as an additive at low temperatures shifts the selectivity of the chloroprene Grignard addition to aldehydes such that it is almost exclusive toward allene formation. In a set of follow-up experiments

  描述了由相应的醛和氯丁二烯衍生的格氏试剂一锅合成外消旋同烯丙基醇的一般程序。在低温下使用双[2-二甲基氨基乙基]醚（BDMAEE）作为添加剂会改变氯丁二烯格利雅（Grignard）除醛以外的选择性，从而几乎不影响丙二烯的形成。在一组后续实验中，已经证明了用于进一步衍生化的简单且更复杂的方法，从而可以快速访问更复杂的结构。
• KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：CHDI Foundation, Inc.

  公开号：EP3130583A1

  公开（公告）日：2017-02-15

  Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising the same and methods of treating patients suffering from certain diseases and disorders response to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof described herein, effective to reduce signs or symptoms of the disease or disorder. These diseases include neurodegenerative disorders such as Huntington's disease.

  本文描述了某些化合物或其药学上可接受的盐或原药、包含这些化合物的药物组合物以及治疗对抑制 KMO 活性有反应的某些疾病和失调患者的方法，其中包括向这些患者施用一定量的本文所述的至少一种化合物或其药学上可接受的盐或原药，以有效减轻疾病或失调的体征或症状。这些疾病包括神经退行性疾病，如亨廷顿氏病。
• Biaryl bruton's tyrosine kinase inhibitors
  申请人：BIOGEN MA INC.

  公开号：US10280169B2

  公开（公告）日：2019-05-07

  The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

  本发明提供了可用作布鲁顿酪氨酸激酶抑制剂并表现出理想特性的化合物及其组合物。
• Nucleoside analogues for the treatment of parasitic infections
  申请人：UNIVERSITEIT GENT

  公开号：US11072628B2

  公开（公告）日：2021-07-27

  The present invention relates to novel nucleoside analogues and compositions containing said nucleoside analogues. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the diagnosis, prevention and/or treatment of parasitic infections, more specifically for use in the diagnosis, prevention and/or treatment of a Trypanosoma infection.

  本发明涉及新型核苷类似物和含有所述核苷类似物的组合物。 此外，本发明还提供了所公开化合物的制备工艺以及使用方法，例如将其用作药物，特别是用于诊断、预防和/或治疗寄生虫感染，更具体地说是用于诊断、预防和/或治疗锥虫感染。
• NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS
  申请人：UNIVERSITEIT GENT

  公开号：US20210024566A1

  公开（公告）日：2021-01-28

  The present invention relates to novel nucleoside analogues and compositions containing said nucleoside analogues. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the diagnosis, prevention and/or treatment of parasitic infections, more specifically for use in the diagnosis, prevention and/or treatment of a Trypanosoma infection.